Sugi Predict

Sugi Predict / Compounds / SCHEMBL1693182

SCHEMBL1693182

SCHEMBL1693182

CC(C)(C)OC(=O)NC1CCCCC1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.50
▸ CA1 P00915 3/20 0.49
▸ CA2 P00918 3/20 0.49
▸ MMP2 P08253 2/20 0.49
▸ MMP9 P14780 2/20 0.49
▸ CA12 O43570 2/20 0.49
▸ CA9 Q16790 2/20 0.49
▸ MMP1 P03956 1/20 0.49
▸ MMP3 P08254 1/20 0.49
▸ MMP8 P22894 1/20 0.49
▸ MMP13 P45452 1/20 0.49
▸ GAA P10253 2/20 0.45
▸ EPHX1 P07099 1/20 0.44
▸ ANPEP P15144 1/20 0.41
▸ ERAP2 Q6P179 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ HDAC4 P56524 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30191451 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL555256 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL3343104 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL3344958 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL555255 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL765453 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL16125648 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL1045289 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL21032211 1.00 BTK (0.50) BTKCA1CA2MMP2MMP9
SCHEMBL23463705 0.98 BTK (0.49) BTKCA1CA2MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114957341-B Spiropyran platinum complex, preparation thereof and application thereof in light-operated hand-light switch material 杭州师范大学 2024-06-25 — — CN claimed
CN-116836032-A Preparation method of cis- (1S, 2R) -N-tert-butoxycarbonyl-1, 2-cyclohexanediamine 泰州葛林美克医药科技有限公司 2023-10-03 — — CN claimed
CN-113999142-B Preparation method of chiral N-Boc-trans-1, 2-cyclohexanediamine 蚌埠中实化学技术有限公司 2023-01-24 — — CN claimed
CN-114957341-A Spiropyran platinum complex, preparation thereof and application thereof in light-operated chiral switch material 杭州师范大学 2022-08-30 — — CN claimed
CN-113999142-A Preparation method of chiral N-Boc-trans-1, 2-cyclohexanediamine 蚌埠中实化学技术有限公司 2022-02-01 — — CN claimed
CN-101597286-A A kind of organic catalyst and preparation thereof that contains primary amine, tertiary amine and urea or thiocarbamide DALIAN CHEMICAL PHYSICS INST (CN) 2009-12-09 — — CN claimed
WO-2025045758-A1 ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF MABLINK BIOSCIENCE (FR) 2025-03-06 — — WO disclosed
WO-2025045761-A1 MOLECULAR GLUE DEGRADERS AND USES THEREOF MABLINK BIOSCIENCE (FR) 2025-03-06 — — WO disclosed
EP-4512806-A1 MOLECULAR GLUE DEGRADERS AND USES THEREOF Mablink Bioscience (FR) 2025-02-26 — — EP disclosed
EP-4512427-A1 ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF Mablink Bioscience (FR) 2025-02-26 — — EP disclosed
CN-119499407-A Fe-based T7 peptide targeted brain glioma micromolecular magnetic resonance contrast agent and preparation and synthesis method and application thereof 中国科学院精密测量科学与技术创新研究院 2025-02-25 — — CN disclosed
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2024-11-21 — — US disclosed
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use JANSSEN PHARMACEUTICA NV (BE) 2024-08-20 — — US disclosed
WO-2003028641-A2 MCH RECEPTOR ANTAGONISTS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-04-10 — — WO disclosed
WO-2003010164-A1 ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-02-06 — — WO disclosed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 — — EP disclosed
CN-1358182-A Respiratory syncytial virus replication inhibitors JANSSEN PHARMACEUTICA NV (BE) 2002-07-10 — — CN disclosed
EP-1196410-A1 RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2002-04-17 — — EP disclosed
EP-1184376-A1 NOVEL HETEROCYCLIC CARBOXAMIDE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2002-03-06 — — EP disclosed
WO-2001000615-A1 RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2001-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use ABL1, BTK, LYN BTK 2/4885CA1 4319/4885CA2 3199/4885
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE ABL1, BTK, MYLK2 BTK 2/4885CA1 4239/4885CA2 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.